Bank of America’s Neumora Therapeutics NMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$345K Buy
176,927
+74,518
+73% +$193K ﹤0.01% 5082
2025
Q4
$183K Sell
102,409
-35,020
-25% -$76.7K ﹤0.01% 5378
2025
Q3
$250K Buy
137,429
+66,049
+93% +$107K ﹤0.01% 6170
2025
Q2
$52.3K Sell
71,380
-797,642
-92% -$604K ﹤0.01% 6796
2025
Q1
$869K Buy
869,022
+773,760
+812% +$1.32M ﹤0.01% 5328
2024
Q4
$1.01M Buy
95,262
+28,364
+42% +$340K ﹤0.01% 5022
2024
Q3
$884K Buy
66,898
+6,788
+11% +$79.2K ﹤0.01% 5129
2024
Q2
$591K Buy
60,110
+38,021
+172% +$393K ﹤0.01% 5245
2024
Q1
$304K Buy
22,089
+6,969
+46% +$113K ﹤0.01% 5650
2023
Q4
$258K Buy
+15,120
New +$186K ﹤0.01% 5928

Other funds holding NMRA

Bank of America's NMRA Position: Q1 2026 in Review

Bank of America increased its Neumora Therapeutics (NMRA) stake by 73% in Q1 2026, buying an estimated $193K and bringing the position to 176,927 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #5082.

Bank of America first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.01M in Q4 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Bank of America held 176,927 shares of Neumora Therapeutics worth $345K as of Q1 2026.
  • Bank of America bought 74,518 Neumora Therapeutics shares in Q1 2026, an estimated $193K.
  • Neumora Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5082 holding.
  • Bank of America first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Bank of America's Neumora Therapeutics position peaked at $1.01M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.